New combo therapy aims to boost immune attack on liver tumors
NCT ID NCT07175441
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 24 times
Summary
This study tests a new drug called RBS2418 combined with two immunotherapy drugs (tremelimumab and durvalumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the combination helps shrink tumors or slows cancer growth better than the immunotherapy drugs alone. About 220 adults will take part, and the study is currently recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins
RECRUITINGBaltimore, Maryland, 21218, United States
-
START Dallas Fort Worth
RECRUITINGFort Worth, Texas, 76104, United States
-
University of Texas Southwestern
RECRUITINGDallas, Texas, 75390, United States
-
Vanderbilt-Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.